<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83406">
  <stage>Registered</stage>
  <submitdate>11/12/2008</submitdate>
  <approvaldate>7/01/2009</approvaldate>
  <actrnumber>ACTRN12609000007235</actrnumber>
  <trial_identification>
    <studytitle>Tyrosine Randomised Controlled Trial in Anorexia Nervosa</studytitle>
    <scientifictitle>In female adolescents with anorexia nervosa, does supplementation with L-tyrosine, when compared with usual treatment alone, lead to improvements in eating disorders psychopathology?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anorexia Nervosa</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Eating disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>L-tyrosine approximately 100mg/kg/day administered orally in capsule form for twelve weeks</interventions>
    <comparator>Placebo (microcrystalline cellulose) 5g/day administered orally in capsule form for twelve weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Eating disorders psychopathology as measured by the Eating Disorders Examination, child version (chEDE)</outcome>
      <timepoint>the chEDE will be administered at baseline and week twelve (completion of the study)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive function tests (including the Rey Complex Figure, Verbal Fluency, Tower of London, Stroop Test, Verbal Paired Associate Learning, Digit Symbol Coding, Visual Learning, Matching, Trail Making tests and Design Fluency)</outcome>
      <timepoint>the cognitive function tests will be administered at baseline and week twelve (completion of the study)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Female adolescents with anorexia nervosa</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>males, children (&lt; 12 years) and adults (18 years and over), those with current (or within 6 months) drug or alcohol abuse, use of dietary tyrosine (or other amino acid) supplements within the previous 12 weeks, medically unstable patients, those with concurrent severe medical or neurological illness and participants with Phenylketonuria (inability to convert phenylalanine to tyrosine) and participants requiring noradrenergic or combined noradrenergic medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>34</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Kenneth Nunn</primarysponsorname>
    <primarysponsoraddress>PO Box 611
Neutral Bay NSW 2089</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Hunter Medical Research Institute</fundingname>
      <fundingaddress>Locked Bag 1
Hunter Region Mail Centre NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The current study aims to investigate the effectiveness of tyrosine (an amino acid found naturally in protein foods) in the treatment of adolescent females with anorexia nervosa.  The design of the study is a double-blind randomized control trial (RCT).  The design will allow for the investigation of the effects of tyrosine in the study population, the testing of process measures, and exploration of recruitment and loss to follow up in clinical trials in people with anorexia nervosa.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Kenneth Nunn</name>
      <address>PO Box 611
Neutral Bay NSW 2089</address>
      <phone>0425353721</phone>
      <fax />
      <email>kpnunn@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melissa Hart</name>
      <address>Child and Adolescent Mental Health Service (CAMHS)
621 Hunter St
Newcastle NSW 2300</address>
      <phone>+61 2 49257800</phone>
      <fax />
      <email>mel.hart@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melissa Hart</name>
      <address />
      <phone />
      <fax />
      <email>mel.hart@hnehealth.nsw.gov.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>